Latest papers

Class of once-weekly diabetes drugs poised for approval.

Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy.

Prevention of diabetes and cardiovascular disease among prediabetic individuals: lifestyle versus drug interventions.

[Adjunctive treatment measures in sepsis and septic shock].

Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.

An update on exenatide, a novel therapeutic option for patients with type 2 diabetes.

Antidiabetic activity of Terminalia sericea constituents.

Transitioning from inpatient to outpatient therapy in patients with in-hospital hyperglycemia.

Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome.

New oral antidiabetic agents.

Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling.

[Drug industry and publication practice].

[Control should be counteracted].

Macrovascular effects and safety issues of therapies for type 2 diabetes.

Type 2 diabetes identified in pregnancy secondary to Cushing's syndrome.

The effect of pioglitazone and resistance training on body composition in older men and women undergoing hypocaloric weight loss.

Mechanism of action of natural products used in the treatment of diabetes mellitus.

Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.

Using insulin in type 2 diabetes: in need of a renaissance?

Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.